Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.

Publication ,  Journal Article
Salama, AKS; Palta, M; Rushing, CN; Selim, MA; Linney, KN; Czito, BG; Yoo, DS; Hanks, BA; Beasley, GM; Mosca, PJ; Dumbauld, C; Steadman, KN ...
Published in: Clin Cancer Res
March 1, 2021

PURPOSE: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma. PATIENTS AND METHODS: Twenty-four patients in two cohorts were enrolled and received ipilimumab at 3 mg/kg every 3 weeks for four doses in conjunction with radiation; median dose was 4,000 cGy (interquartile range, 3,550-4,800 cGy). Patients in cohort 1 were treated adjuvantly; patients in cohort 2 were treated either neoadjuvantly or as definitive therapy. RESULTS: Adverse event profiles were consistent with those previously reported with checkpoint inhibition and radiation. For the neoadjuvant/definitive cohort, the objective response rate was 64% (80% confidence interval, 40%-83%), with 4 of 10 evaluable patients achieving a radiographic complete response. An additional 3 patients in this cohort had a partial response and went on to surgical resection. With 2 years of follow-up, the 6-, 12-, and 24-month relapse-free survival for the adjuvant cohort was 85%, 69%, and 62%, respectively. At 2 years, all patients in the neoadjuvant/definitive cohort and 10/13 patients in the adjuvant cohort were still alive. Correlative studies suggested that response in some patients were associated with specific CD4+ T-cell subsets. CONCLUSIONS: Overall, concurrent administration of ipilimumab and radiation was feasible, and resulted in a high response rate, converting some patients with unresectable disease into surgical candidates. Additional studies to investigate the combination of radiation and checkpoint inhibitor therapy are warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

March 1, 2021

Volume

27

Issue

5

Start / End Page

1287 / 1295

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Rate
  • Radiotherapy Dosage
  • Prospective Studies
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Middle Aged
  • Melanoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Salama, A. K. S., Palta, M., Rushing, C. N., Selim, M. A., Linney, K. N., Czito, B. G., … Brizel, D. M. (2021). Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clin Cancer Res, 27(5), 1287–1295. https://doi.org/10.1158/1078-0432.CCR-20-2452
Salama, April K. S., Manisha Palta, Christel N. Rushing, M Angelica Selim, Kristen N. Linney, Brian G. Czito, David S. Yoo, et al. “Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.Clin Cancer Res 27, no. 5 (March 1, 2021): 1287–95. https://doi.org/10.1158/1078-0432.CCR-20-2452.
Salama AKS, Palta M, Rushing CN, Selim MA, Linney KN, Czito BG, et al. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clin Cancer Res. 2021 Mar 1;27(5):1287–95.
Salama, April K. S., et al. “Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.Clin Cancer Res, vol. 27, no. 5, Mar. 2021, pp. 1287–95. Pubmed, doi:10.1158/1078-0432.CCR-20-2452.
Salama AKS, Palta M, Rushing CN, Selim MA, Linney KN, Czito BG, Yoo DS, Hanks BA, Beasley GM, Mosca PJ, Dumbauld C, Steadman KN, Yi JS, Weinhold KJ, Tyler DS, Lee WT, Brizel DM. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clin Cancer Res. 2021 Mar 1;27(5):1287–1295.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

March 1, 2021

Volume

27

Issue

5

Start / End Page

1287 / 1295

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Rate
  • Radiotherapy Dosage
  • Prospective Studies
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Middle Aged
  • Melanoma